Mentee for End Stage Renal Disease (ESRD)

Phase-Based Progress Estimates
Satellite Healthcare Mountain View, Mountain View, CA
End Stage Renal Disease (ESRD)+1 More
Mentoring - Behavioral
All Sexes
What conditions do you have?

Study Summary

Peer mentoring is an approach used to support patients through their experience. In the End Stage Kidney Disease community many patients find out about their kidney failure without warning. This study is designed to test the feasibility of a structured peer support program, specifically, patient uptake, engagement and patient and staff perspectives.

Eligible Conditions

  • End Stage Renal Disease (ESRD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for End Stage Renal Disease (ESRD)

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: 3,6,9 and 12 months

1 month
Mentor - Mentee Matching
1-4 weeks
Mentee Perspectives
3,6,9 and 12 months
Support Staff Perspectives
6 - 12 months
Mentor Perspectives

Trial Safety

Safety Progress

1 of 3

Other trials for End Stage Renal Disease (ESRD)

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Mentee · No Placebo Group · N/A

Experimental Group · 1 Intervention: Mentoring · Intervention Types: Behavioral
First Studied
Drug Approval Stage
How many patients have taken this drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3,6,9 and 12 months
Closest Location: Satellite Healthcare Mountain View · Mountain View, CA
2022First Recorded Clinical Trial
1 TrialsResearching End Stage Renal Disease (ESRD)
1 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a mentor patient.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.